Johnson & Johnson announces encouraging first-in-human clinical data for investigational HIV preventive vaccine
|
26 July 2017 |
Health risk assessments shed light on early predictors of depression
|
11 April 2017 |
Johnson & Johnson reports that investigational Ebola vaccine regimen induced durable immune response 1 year after vaccination in Phase 1 study
|
15 March 2017 |
Johnson & Johnson completes acquisition of Abbott Medical Optics
|
01 March 2017 |
Esketamine receives Breakthrough Therapy Designation from FDA for major depressive disorder with imminent risk for suicide
|
17 August 2016 |
Johnson & Johnson announces collaboration with HP Inc. subsidiary to create personalized health care solutions with 3D printing technologies
|
17 May 2016 |
Johnson & Johnson announces launch of new global public health strategy at opening of new operations in Africa
|
06 April 2016 |
Johnson & Johnson issues call for innovative ideas to reduce HIV infections in Sub-Saharan Africa
|
24 February 2016 |
Daratumumab combined with standard treatment for multiple myeloma produced deep and durable responses in relapsed or refractory patients
|
07 December 2015 |
Johnson & Johnson announces agreement to acquire Novira Therapeutics, Inc.
|
04 November 2015 |
Johnson & Johnson announces completion of Cordis divestiture to Cardinal Health
|
08 October 2015 |
Johnson & Johnson announces BARDA funding award to accelerate Ebola vaccine program
|
14 September 2015 |